Abstract
Many years passed between the time that Pasteur (1878)1first cultivated the hemolytic streptococcus from a patient with puerperal sepsis and the time that attempts were made to combat the disease with serum. Of all the bacteria that may produce puerperal sepsis, the hemolytic streptococcus has been found the most common invader in the fatal types of the infection. Since 1895, when Marmorek2produced a serum which was supposedly valuable in the treatment of all types of streptococcic infections, other investigators3employed polyvalent serums with discouraging results. Of all the types of serum therapy for puerperal sepsis subsequently reported,4the most promising employed human convalescent serum.4bHowever, the inadequacy of the supply made this mode of therapy impracticable. The Dicks5demonstrated the importance of streptococcus antitoxin in the treatment of scarlet fever by a controlled therapeutic study. In one series of patients with moderately
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
